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Abstract. Human and bovine serum albumins are the most common proteins in the circulatory 
system of many organisms. Numerous studies are regarding their interactions with different types of 
ligands. These interactions are important for their applicability in many areas in biomedical field. The 
interaction of human serum albumin (HSA) and bovine serum albumin (BSA) with vitamin B12 was 
investigated using UV absorption and fluorescence spectroscopy. Results showed that the absorption 
and fluorescence intensities decreased as vitamin C concentration increases. The calculated binding 
constant (k ~104 M–1) showed a weak binding of vitamin B12 with both serum albumins. The analysis 
of fluorescence quenching for HSA/BSA-vitamin B12 interaction (kq ~ 1012 [L] mol–1⋅s–1, where kq is 
the protein bimolecular quenching rate, and [L] represents the concentrations of the quencher) reveals 
the dynamic quenching process and clearly confirms the existence of a static mechanism of 
fluorescence quenching.  
Key words: Human serum albumin, bovine serum albumin, vitamin B12, UV-absorption, 
fluorescence spectroscopy, binding constant, binding mode. 
INTRODUCTION 
Vitamin B12 (known as cyanocobalamin) has the molecular formula 
C63H88CoN14O14P, molecular weight of 1355.388 g⋅mol–1 and its chemical structure 
is shown in Figure 1 [18]. Vitamin B12, the only biomolecule with carbon-metal 
bond, is a red-colored water-soluble complex based on a corrin ring [1]. Commercially 
available cyanocobalamin is a stable form generated industrially only through a 
bacterial fermentation-synthesis, which is quickly transformed to methylcobalamin 
and then to adenosylcobalamin in human organism [2]. The estimated average 
requirements for this vitamin are in the range of 0.4–2.8 µg⋅day–1, depending on the 
sex, age and condition [3]. Vitamin B12 is indispensable for humans and mammals, 
participating in the formation of red blood cells and in the maintenance of a healthy 
brain and nervous system [38]. Additionally, it is an enzyme cofactor in many 
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metabolic processes, antioxidant and modulator of nucleic acid metabolism and 
gene regulation [9]. Therefore, vitamin B12 deficiency reported mainly in case of 
infants, vegetarians or ill persons, can be associated with megaloblastic anemia, 
hyperhomocysteinemia and various neurological disorders, including memory 
problems, Parkinson and Alzheimer diseases [22, 30]. The deficiency of vitamin B12 
can be a risk factor for coronary heart disease and stroke, as well as for the 
symptoms of mania, psychosis or depression [12, 34, 37]. A decreased level of this 
compound is mainly a consequence of its low intakes, but can result as well from 
less absorption, especially in smoker’s case (since nicotine can block its absorption), 
alcoholism, certain intestinal disorders (celiac or Crohn’s diseases), low presence 
of binding proteins and use of certain medications [9, 13, 20]. 
 
Fig. 1. Chemical structure of the basic form of vitamin B12. 
The binding of several different categories of small molecules to serum albumins 
has been studied for many years through different spectroscopic techniques to 
elucidate details of the protein structure and binding mechanism. The binding affinity 
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of vitamin B12 with HSA was studied using UV absorption and fluorescence 
spectroscopy in addition to circular dichroism. The results showed that the 
mechanism of interaction has been found to be a dynamic quenching. The effect of B12 
on the conformation of HSA was analyzed. The results indicated that the polarity 
around the tryptophan residues of HSA was decreased and its hydrophobicity was 
increased [23, 32]. Serum albumin or blood albumin is the most abundant protein 
present in the circulatory system of vertebrates, synthesized in the liver and, being 
a major macromolecule, it contributes to osmotic blood pressure [3]. It can play a 
dominant role in drug disposition and efficiency [40, 43]. Many anesthetic and 
other bioactive small molecules bind reversibly to albumin and other serum com-
ponents, which then can function as carriers. The apparent solubility of hydrophobic 
drugs in plasma is increased by serum albumin and modulates their delivery to cell 
in vivo and in vitro. Animal experiments were used to provide basic knowledge on 
the pharmacological actions, biotransformation and biodistribution of drugs [46]. 
Bovine serum albumin is suitable to these studies, because it has been extensively 
characterized [29]. Similarly, human serum albumin constitutes about 60% of the 
serum protein; its function is to transport and dispose many endogenous and exogenous 
substances such as metabolites, drugs, and other biologically active compounds 
present in the blood [6]. BSA and HSA are frequently used in biophysical and 
biochemical studies since they have a similar folding, a well-known primary structure, 
and they have been associated with the binding of many different categories of 
small molecules. One important difference of BSA and HSA is the fact that bovine 
albumin has two tryptophan residues while human albumin has a unique tryptophan 
[18]. Recently, its three-dimensional (3D) structure has been determined through 
X-ray crystallographic measurements [23] and consists of three structurally homo-
logous domains which assemble to form a heart-shaped molecule, each domain 
containing two sub-domains. Serum albumin binds and transports many ligands, 
including fatty acids, amino acids, hormones, cations, anions, and a variety of 
pharmaceuticals. It is suggested that the principal regions of ligand binding to HSA 
are located in hydrophobic, and single tryptophan residue of HSA [4, 8, 24, 31, 32]. 
In order to gain general fundamental insights into protein-drug binding, the drug-
albumin complex was considered as a model. The binding of drugs to plasma 
protein is considered very important, since it influences their pharmacokinetic and 
pharmacodynamic properties and may also cause interference with the binding of 
other endogenous and/or exogenous ligands as a result of the overlap of binding 
sites and/or conformational changes. Therefore, a detailed investigation of drug-protein 
interaction assumes significance for a thorough understanding of the pharmacokinetic 
behavior of a drug and for the design of analogues with effective pharmacological 
properties [32]. There are some popular techniques which have been used to 
investigate the interaction between drugs and proteins. UV-absorption and fluorescence 
spectroscopy are the powerful techniques to study molecular interactions which 
change local environment of fluorophore and help to predict the binding phenomenon 
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of drugs to proteins [5]. Fluorescence quenching is a powerful method to investigate 
the reactivity of chemical and biological systems because it allows non-intrusive 
measurements of substances in low concentration under physiological conditions 
[6, 25, 32]. It can reveal accessibility of quenchers to serum albumins fluorophores, 
help to understand serum albumins binding mechanisms to compounds and provides 
clues to the nature of the binding phenomenon.  
The aim of the present work is to study the interaction between BSA and 
HSA with vitamin B12. This study is highly important for pharmaceutical sciences 
to clarify the structure, function, and properties of BSA/HAS-vitamin B12 complexes. 
Investigations of the interaction mechanisms and the binding constant between 
vitamin B12 and BSA/HSA should be provided. In order to attain these objectives, 
UV-Vis absorption spectroscopy, ﬂuorescence spectroscopy and FTIR spectroscopy 
were employed to carry out detailed investigation. 
MATERIALS AND METHODS 
MATERIALS 
BSA and HSA (purity > 99%) was purchased from Sigma Aldrich Company, 
and vitamin C was purchased from Al-Quds Co. pharmaceutical chemical industries, 
their solutions were prepared in phosphate buffer solutions (pH = 7.4). The other 
substances are of reagent grade and were used without further purifications. 
A final concentration of (40 mg/mL) of HSA and BSA was used in the final 
vitamin C-protein solution, then the solution was placed in ultrasonic water path 
(SIBATA AU-3T) for one hour to ensure that all the amount of vitamin B12 was 
completely dissolved. The final concentrations of vitamin B12-protein complexes 
were prepared by mixing equal volumes of HSA and BSA to equal volume from 
different concentrations of vitamin B12. HSA and BSA concentrations in all samples 
were kept at 40 mg⋅mL–1. The final concentrations of vitamin B12 are (40, 20, 10, 5, 2 
and 1 mg⋅mL–1). The solution was incubated for 1 h (at 25°C) before spectroscopic 
measurements were taken. 
INSTRUMENTS 
UV-VIS spectrophotometer 
The mixed sample was placed in a 1.0 cm quartz cuvette, and the absorption 
spectra of the system at wavelengths of 220–750 nm were recorded using a NanoDrop 
ND-1000 spectrophotometer (Shimadzu, Kyoto, Japan) at room temperature (298 K) 
with a scanning speed of 300 nm/min with high accuracy and reproducibility. The 
background absorbance of the buffer solution was subtracted from the sample 
absorbance. 
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Fluorescence spectrometer 
The fluorescence measurements were performed by a NanoDrop ND-3300 
Fluoro-spectrophotometer at 25°C. The excitation source comes from one of three 
solid-state light emitting diodes (LEDs). The excitation source options include: UV 
LED with maximum excitation 365 nm, blue LED with excitation at 470 nm, and 
white LED from 500 to 650 nm excitation. A 2048-element CCD array detector 
covering 400–750 nm is connected by an optical fiber to the optical measurement 
surface. The excitation is done at the wavelength of 360 nm and the maximum 
emission wavelength is at 439 nm. 
The absorption and emission spectra were recorded for free HSA and BSA at 
40 mg⋅mL–1 and for its complexes with vitamin B12 solution with the concentrations of 
40, 20, 10, 5, 2 and 1 mg⋅mL–1. Repeated measurements were done for all samples. 
RESULTS AND DISCUSSION 
UV ABSORPTION SPECTRA 
UV-Vis absorption spectroscopy is one of the common and effective experi-
mental techniques used in calculating binding constants for several drug-protein 
complexes [26]. To initially verify the quenching mechanism, the UV absorption 
spectra of HSA/BSA-vitamin B12 were measured and recorded. Complex has formed 
by the interaction of vitamin B12 with HSA/BSA as shown from the absorption data 
in Figure 2. The intensity of UV-absorption of both proteins (absorption peak 278 nm) 
decreased with increasing concentrations of vitamin B12 indicating formation of 
vitamin B12-HSA/BSA complex. 
 
                           (a)               (b) 
Fig. 2. UV-absorption spectra of different concentrations of vitamin B12 (a = free HSA,  
b = 1, c = 2, d = 5, e = 10, f = 20, and g = 40 mg⋅mL–1) with (a). HSA, (b). BSA.  
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Vitamin B12-HSA/BSA binding constants have been determined using UV-
absorbance spectroscopy, by assuming only one type of interaction between ligand 
and proteins in aqueous solution. The absorption data were treated using linear 
reciprocal plots based on the following equation [39]. 
  (1) 
where A0 corresponds to the initial absorption of protein at 280 nm in the absence 
of ligand, A∞ is the final absorption of the ligated protein, and A is the recorded 
absorption at different vitamin B12 concentrations ([L]).  
The double reciprocal plot of 1/(A – A0) vs. 1/[L] is linear (Fig. 3) and the 
binding constants (k) can be estimated from the ratio of the intercept to the slope. 
The obtained values of the binding constants indicate a relatively weak interaction 
of vitamin B12 with HSA (k = 2.21×104 M–1) and with BSA (k = 1.61×104 M–1). 
The binding constant values show a relatively weak vitamin B12-HSA/BSA interaction 
in comparison to other drug–protein complexes with binding constants in the range 
of 105 and 106 M–1 [7, 18, 26]. The reason for the low stability can be attributed to 
the presence of mainly hydrogen-bonding interaction between protein donor atoms 
and the ligand polar groups or an indirect drug-protein interaction through water 
molecules [33]. 
 
Fig. 3. The plot of 1/(A – A0) vs 1/[L] for HSA and BSA  
with different concentrations of vitamin B12. 
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FLUORESCENCE SPECTROSCOPY 
The ligand-binding process during protein-ligand complex is mainly governed 
by four types of weak, noncovalent forces including hydrogen bond, van der Waals 
force, electrostatic, and hydrophobic interactions [42]. Fluorescence quenching 
studies to explore the binding interaction of drug ligands with proteins is considered as 
the best methodology [15]. This quenching resulted from the reduction of quantum 
yield of fluorescence from a fluorophore induced by a variety of molecular interactions 
with a quencher molecule [10–11, 30]. An Increase in the concentration of quencher 
will mask the fluorophore, resulting in reduction of emitted fluorescence from the 
fluorophore molecules. In ease of targeting specific location regarding the binding 
pattern of protein, we used different wavelengths. Generally, the fluorescence of 
HSA and BSA comes from tryptophan, tyrosine and phenylalanine residues. During 
data recording at an excitation wavelength at 280 nm, fluorescence of albumin was 
coming from both tryptophan and tyrosine residues, whereas 293 nm wavelength 
excited tryptophan residues only [44]. 
Figure 4 represents the fluorescence spectra of HSA and BSA in combination 
with different concentrations of vitamin B12. It was observed that fluorescence 
spectrum exhibited the peak maximum at 440 nm for HSA/BSA-vitamin B12 
complexes. The fluorescence intensity decreases with increasing concentrations of 
vitamin B12. This indicated that there was some alteration in the microenvironment 
of the fluorophore Trp-213 upon interaction of both proteins with vitamin B12. 
 
                                    (a)                (b) 
Fig. 4. Fluorescence emission spectra in the absence and presence of vitamin B12  
(a = free (HSA (a), BSA (b), b = 1, c = 2, d = 5, e = 10, f = 20 and g = 40 mg⋅mL–1). 
The mechanism by which small molecule ligands quench the flouresence of 
plasma albumin is mainly divided into dynamic quenching and static quenching. In 
dynamic quenching, the excited molecules of the fluorescent substance collide with 
the quencher molecules and, through energy transfer or charge transfer, the excited 
molecules lose their excitation energy and return to the ground state without 
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emitting photons. In static quenching, the quenching agent and fluorescent substance in 
the ground state form a complex, leading to fluorescence quenching [28, 36]. Quenching 
constant values depend on temperature; they increase as temperature values go up. 
For dynamic quenching, a faster diffusion results as temperature increases [21]. 
However, static quenching results from the decrement of temperature values [27]. 
In order to analyze the fluorescence quenching mechanism, the Stern-Volmer 
equation [45] was used: 
  (2) 
where F0 and F are protein (HSA and BSA) fluorescence intensities in the absence 
and presence of quencher (vitamins C);  is the average fluorescence lifetime of 
protein molecule without quencher (of the order of 10–8 [36]), ksv is Stern-Volmer 
fluorescence quenching constant. 
In Figure 5 is shown the Stern-Volmer plot of both complexes fluorescence 
intensities. The two plots showed good a linear relationship, suggesting the existence 
of a single type of quenching (dynamic or static) and/or a single binding site. The 
values of the fluorescence quenching constant determined by applying Eq. (2) are 
equal to 2.97×104, 2.42×104 [L] mol–1 for HSA/BSA-vitamin B12, respectively, 
both values are much lower than other ksv values for the similar systems signalized 
earlier in literature [12, 45]. The values of kq which are equal to 2.97×1012, 
2.42×1012 [L] mol–1⋅s–1 for HSA/BSA-vitamin B12 respectively. These values confirm 
clearly the existence of the static (diffusion-independent) mechanism of fluorescence 
quenching [16, 37, 41]. 
 
Fig. 5. The Stern-Volmer plot for HSA/BSA-vitamin C complexes. 
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When static quenching is dominant, the modified Stern-Volmer equation 
could be used [46] 
  (3) 
where k is the binding constant. 
A plot of  vs  is presented in Figure 6. The two plots are linear and 
have a slope of  and intercept  according to eq. (3). The values of k were 
found to be 2.29×104 M–1, 1.44×104 M–1 for HSA/BSA-vitamin B12 respectively, 
which agrees well with the value obtained earlier by UV spectroscopy. The low 
effective quenching constant in this case has led to a lower value of binding 
constant between HSA/BSA-vitamin B12 complexes due to an effective hydrogen 
bonding between vitamin B12 and proteins. The interaction between vitamin molecules 
with proteins is initiated by electrostatic forces, but subsequently the hydrophobic 
interactions make the major role for vitamin B12 and proteins interaction. 
 
Fig. 6. The plot of 1/(F0 – F) vs. 1/[L]×105 for HSA/BSA-vitamin B12 complexes. 
CONCLUSIONS 
Serum albumins play a key role in the transport, distribution, metabolism and 
excretion of drugs molecules. In order to develop a new and effective drug, we 
have to study the ability of drug binding to albumins. In this work, the interaction 
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between HSA/BSA-vitamin B12 was investigated by fluorescence and UV spectro-
scopic techniques. The results showed that the fluorescence of HSA and BSA 
would be quenched with the addition of vitamin B12. This change was via static 
quenching. The calculated binding constants of the interaction of vitamin B12 with 
both proteins using both techniques showed a good agreement but the values were 
found to be relatively weak. 
The results reported in this work are important in the field of pharmacology 
and biochemistry and can be used to understand the effect of vitamin B12 on protein 
function during the blood transportation process. The clear information presented 
in this study may be used to provide some information for its rational use in 
clinical practice. 
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